- Home
- AXL vs PVLA Comparison
AXL vs PVLA Comparison
Compare AXL & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXL
- PVLA
- Stock Information
- Founded
- AXL 1994
- PVLA 2015
- Country
- AXL United States
- PVLA United States
- Employees
- AXL N/A
- PVLA N/A
- Industry
- AXL Auto Parts:O.E.M.
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- AXL Consumer Discretionary
- PVLA Health Care
- Exchange
- AXL Nasdaq
- PVLA Nasdaq
- Market Cap
- AXL 715.5M
- PVLA 604.2M
- IPO Year
- AXL 1999
- PVLA N/A
- Fundamental
- Price
- AXL $6.51
- PVLA $73.13
- Analyst Decision
- AXL Buy
- PVLA Strong Buy
- Analyst Count
- AXL 7
- PVLA 12
- Target Price
- AXL $6.93
- PVLA $68.67
- AVG Volume (30 Days)
- AXL 3.3M
- PVLA 199.5K
- Earning Date
- AXL 11-07-2025
- PVLA 11-15-2025
- Dividend Yield
- AXL N/A
- PVLA N/A
- EPS Growth
- AXL 3967.82
- PVLA N/A
- EPS
- AXL 0.35
- PVLA N/A
- Revenue
- AXL $5,833,200,000.00
- PVLA N/A
- Revenue This Year
- AXL N/A
- PVLA N/A
- Revenue Next Year
- AXL N/A
- PVLA N/A
- P/E Ratio
- AXL $18.69
- PVLA N/A
- Revenue Growth
- AXL N/A
- PVLA N/A
- 52 Week Low
- AXL $3.00
- PVLA $11.17
- 52 Week High
- AXL $7.03
- PVLA $77.77
- Technical
- Relative Strength Index (RSI)
- AXL 64.96
- PVLA 58.85
- Support Level
- AXL $5.37
- PVLA $70.55
- Resistance Level
- AXL $5.77
- PVLA $77.77
- Average True Range (ATR)
- AXL 0.26
- PVLA 4.95
- MACD
- AXL 0.07
- PVLA -0.60
- Stochastic Oscillator
- AXL 91.60
- PVLA 64.19
About AXL American Axle & Manufacturing Holdings Inc.
American Axle & Mfg Holdings Inc is engaged in manufacturing, engineering, designing, and validation of driveline systems and related components and chassis modules for light trucks, SUVs, crossover vehicles, passenger cars, and commercial vehicles. The company's segment includes Driveline and Metal Forming. It generates maximum revenue from the Driveline segment.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.